Evvy raises $40M to take its microbiome dataset into fertility
Evvy said on Tuesday it has closed an oversubscribed $40 million Series B led by Catalio Capital Management. The women’s health company sells an at-home vaginal microbiome test, so it plans to spend the money validating AI driven diagnostic models, starting with fertility.
Catalio came in alongside new backers Rethink Impact, Muse Capital and Alumni Ventures, according to the company’s announcement. Existing investors LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital and Flywheel Ventures joined too.
The mechanism behind that money is a swab. Patients collect a sample at home and mail it to Evvy’s lab, and TechCrunch reported that results go to clinicians registered on the platform before they reach a patient portal. Evvy says the test uses CLIA-certified, CLEP-approved metagenomic sequencing and screens for more than 700 microbes.
Those results then feed EvvyAI, which the release calls a machine learning engine that interprets large-scale biological data. The bet is that biology becomes a data problem at scale, the same premise behind DeepMind scoring 9 billion human DNA variants in AlphaGenome Atlas. Evvy says clinicians using the platform deliver a diagnosis to more than 90% of symptomatic patients, and cut bacterial vaginosis recurrence by roughly half.
| Figure | Evvy’s number | Where it comes from |
|---|---|---|
| Series B | $40M, oversubscribed | Company announcement |
| Patients served | 100,000+ | Company announcement |
| Practitioners on platform | 3,000 | Company announcement |
| Misdiagnosis rate, traditional care | 50%+ | Company announcement, no study cited |
| Recurrence rate, traditional care | 60%+ | Company announcement, no study cited |
| Peer-reviewed papers and abstracts | 13, or 15 and up | Release body vs release boilerplate |
Women hear ‘unexplained’ constantly, whether it’s unexplained infertility, unexplained recurrence, unexplained pain.
Priyanka Jain, co-founder and CEO of Evvy, via SiliconANGLE
Jain told SiliconANGLE that the word gets stated like a diagnosis when it really means medicine wasn’t built to measure female biology. She dated the gap precisely, because drug trials generally excluded women until 1993, which leaves roughly 30 years of research data on female biology.
Every outcome figure above comes from Evvy, and the comparison numbers carry no citation in the release. The company’s own science page does list published work, including a study of more than 1,000 patients reporting 75% symptom resolution and a 50% drop in BV recurrence. Even the publication count isn’t settled internally, since the release body says 13 while its boilerplate and the science page say 15 or more.
But treatment is only half the pitch, because fertility is the first expansion beyond vaginal health. Evvy says it’s continuing a collaboration with US Fertility, which the release calls the nation’s largest network of fertility clinics, and TechCrunch reported the company launched a prospective study in IVF clinics last year. Fortune reported the project aims to identify novel markers of infection and inflammation that predict whether implantation succeeds.
Evvy isn’t the only company chasing that data, though. TechCrunch named Juno Bio, Tiny Health and Daye as others working on vaginal health, and Jain told Fortune that investors pressed her toward an easier business, asking why she didn’t just become a supplements company. At $40 million the round is small next to AI raises like Stability AI’s $76M Series B, though it buys the clinical-grade dataset Evvy claims is the world’s largest.
We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it.
Jacob Vogelstein, co-founder and managing partner, Catalio Capital Management
What to watch is whether the fertility work holds up outside Evvy’s own cohort. Jain told SiliconANGLE the company has identified six distinct BV subtypes, and said it would share more fertility findings later this year. Until an independent group replicates the link between microbiome profiles and IVF outcomes, that $40 million is buying evidence the field doesn’t yet have.
Get the daily rundown
One email each weekday with the AI news that matters, every claim linked to its primary source.
Free, one email each weekday, unsubscribe in one click. We never sell or share your address.
